A life-extending treatment for an aggressive form of cancer has been given the green light for NHS use, offering new hope to patients battling bile duct cancer. Health officials have recommended zanidatamab for those diagnosed with cholangiocarcinoma, a disease often identified at a late stage when surgical removal is no longer an option.
Clinical trials indicate that the new treatment could almost triple the life expectancy of patients compared with existing therapies. This is particularly significant given that fewer than one in three people diagnosed in England survive a year post-diagnosis, and treatment options have historically been limited.
